Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver.

Transduction with recombinant adeno-associated virus (AAV) vectors is limited by the need to convert its single-stranded (ss) genome to transcriptionally active double-stranded (ds) forms. For AAV-mediated hemophilia B (HB) gene therapy, we have overcome this obstacle by constructing a liver-restricted mini-human factor IX (hFIX) expression cassette that can be packaged as complementary dimers within individual AAV particles. Molecular analysis of murine liver transduced with these self-complementary (sc) vectors demonstrated rapid formation of active ds-linear genomes that persisted stably as concatamers or monomeric circles. This unique property resulted in a 20-fold improvement in hFIX expression in mice over comparable ssAAV vectors. Administration of only 1 x 10(10) scAAV particles led to expression of hFIX at supraphysiologic levels (8I U/mL) and correction of the bleeding diathesis in FIX knock-out mice. Of importance, therapeutic levels of hFIX (3%-30% of normal) were achieved in nonhuman primates using a significantly lower dose of scAAV than required with ssAAV. Furthermore, AAV5-pseudotyped scAAV vectors mediated successful transduction in macaques with pre-existing immunity to AAV8. Hence, this novel vector represents an important advance for hemophilia B gene therapy.

[1]  Brian Seed,et al.  Codon usage limitation in the expression of HIV-1 envelope glycoprotein , 1996, Current Biology.

[2]  J. Rasko,et al.  1002. Immune Responses to AAV and to Factor IX in a Phase I Study of AAV-Mediated, Liver-Directed Gene Transfer for Hemophilia B , 2004 .

[3]  J. Gray,et al.  Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock. , 2004, Journal of virological methods.

[4]  Lili Wang,et al.  Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Theresa A. Storm,et al.  Unrestricted Hepatocyte Transduction with Adeno-Associated Virus Serotype 8 Vectors in Mice , 2005, Journal of Virology.

[6]  M. Kay,et al.  Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  S. Amadori,et al.  Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. , 2004, Blood.

[8]  M. Brittan,et al.  Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy. , 2004, Blood.

[9]  M. Weitzman,et al.  Recruitment of wild-type and recombinant adeno-associated virus into adenovirus replication centers , 1996, Journal of virology.

[10]  M. Zoppè,et al.  A factor IX-deficient mouse model for hemophilia B gene therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[11]  D. Russell,et al.  DNA-damaging agents greatly increase the transduction of nondividing cells by adeno-associated virus vectors , 1994, Journal of virology.

[12]  M. Kay,et al.  A Limited Number of Transducible Hepatocytes Restricts a Wide-Range Linear Vector Dose Response in Recombinant Adeno-Associated Virus-Mediated Liver Transduction , 2002, Journal of Virology.

[13]  Jody A. Vandergriff,et al.  Efficient gene transfer into human cord blood CD34+ cells and the CD34+CD38− subset using highly purified recombinant adeno-associated viral vector preparations that are free of helper virus and wild-type AAV , 2000, Gene Therapy.

[14]  R. Samulski,et al.  Rescue of adeno-associated virus from recombinant plasmids: Gene correction within the terminal repeats of AAV , 1983, Cell.

[15]  E. Freese,et al.  Prospects of gene therapy. , 1972, Science.

[16]  Theresa A. Storm,et al.  Extrachromosomal Recombinant Adeno-Associated Virus Vector Genomes Are Primarily Responsible for Stable Liver Transduction In Vivo , 2001, Journal of Virology.

[17]  A. Davidoff,et al.  Prospects for gene therapy of haemophilia , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[18]  A. Davidoff,et al.  Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. , 2003, Blood.

[19]  A. Nienhuis,et al.  Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. , 2001, Blood.

[20]  R. Morgan,et al.  The rhesus macaque as an animal model for hemophilia B gene therapy. , 1999, Blood.

[21]  O. Christophe,et al.  Functional mapping of anti-factor IX inhibitors developed in patients with severe hemophilia B. , 2001, Blood.

[22]  R. Kotin,et al.  Virus-Mediated Transduction of Murine Retina with Adeno-Associated Virus: Effects of Viral Capsid and Genome Size , 2002, Journal of Virology.

[23]  R. Samulski,et al.  Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo , 2003, Gene Therapy.

[24]  Linda Yang,et al.  Cloning and Characterization of Adeno-Associated Virus Type 5 , 1999, Journal of Virology.

[25]  E. Tuddenham,et al.  Epidemiology of coagulation disorders. , 1992, Bailliere's clinical haematology.

[26]  C. Slaughter,et al.  Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. , 2002, Blood.

[27]  C. Lewis,et al.  Mutation rates in humans. I. Overall and sex-specific rates obtained from a population study of hemophilia B. , 1999, American journal of human genetics.

[28]  Arun Srivastava,et al.  Adeno-Associated Virus Type 2-Mediated Gene Transfer: Role of Epidermal Growth Factor Receptor Protein Tyrosine Kinase in Transgene Expression , 1998, Journal of Virology.

[29]  D. Russell,et al.  Design and Packaging of Adeno-Associated Virus Gene Targeting Vectors , 2000, Journal of Virology.

[30]  Theresa A. Storm,et al.  Rapid Uncoating of Vector Genomes Is the Key toEfficient Liver Transduction with Pseudotyped Adeno-Associated VirusVectors , 2004, Journal of Virology.

[31]  R. Samulski,et al.  Cross-Packaging of a Single Adeno-Associated Virus (AAV) Type 2 Vector Genome into Multiple AAV Serotypes Enables Transduction with Broad Specificity , 2002, Journal of Virology.

[32]  J. Zhang,et al.  Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo , 2003, Gene Therapy.

[33]  G. Boiteau,et al.  J. Virol. Methods , 1996, Journal of Virological Methods.

[34]  R. Samulski,et al.  Production of High-Titer Recombinant Adeno-Associated Virus Vectors in the Absence of Helper Adenovirus , 1998, Journal of Virology.

[35]  M. Weitzman,et al.  Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis , 1996, Journal of virology.

[36]  P. Lenting,et al.  Residues Phe342–Asn346 of Activated Coagulation Factor IX Contribute to the Interaction with Low Density Lipoprotein Receptor-related Protein* , 2003, The Journal of Biological Chemistry.

[37]  J. Gray,et al.  Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.